Search Results - "Marinos, C"

Inflammatory Muscle Diseases by Dalakas, Marinos C

“…The four main types of inflammatory muscle disease — dermatomyositis, polymyositis, necrotizing autoimmune myositis, and inclusion-body myositis — are…”
Get full text

Immunotherapy in myasthenia gravis in the era of biologics by Dalakas, Marinos C.

“…No consensus has been reached on the ideal therapeutic algorithm for myasthenia gravis (MG). Most patients with MG require induction therapy with high doses of…”
Get full text

Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing by Dalakas, Marinos C.

“…To present the COVID-19-associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19-triggered autoimmunities,…”
Get full text

Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies by Dalakas, Marinos C.

“…Although antibodies against Glutamic Acid Decarboxylase (GAD) were originally associated with Stiff Person Syndrome (SPS), they now denote the “GAD…”
Get full text

Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies by Dalakas, Marinos C.

“…To provide an update on immunomodulating and immunosuppressive therapies in myasthenia gravis and highlight newly approved, or pending approval, therapies with…”
Get full text

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy by Dalakas, Marinos C.

“…In the last 25 years, intravenous immunoglobulin (IVIg) has had a major impact in the successful treatment of previously untreatable or poorly controlled…”
Get full text

Cranial neuropathies and COVID-19: Neurotropism and autoimmunity by Costello, Fiona, Dalakas, Marinos C.

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or “COVID-19” global pandemic began in late 2019. Like its predecessors, SARS-CoV and Middle…”
Get full text

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system by Dalakas, Marinos C.

“…Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications…”
Get full text

Complement in neurological disorders and emerging complement-targeted therapeutics by Dalakas, Marinos C., Alexopoulos, Harry, Spaeth, Peter J.

“…The complement system consists of a network of plasma and membrane proteins that modulate tissue homeostasis and contribute to immune surveillance by…”
Get full text

Pathogenesis of immune-mediated neuropathies by Dalakas, Marinos C.

“…Autoimmune neuropathies occur when immunologic tolerance to myelin or axonal antigens is lost. Even though the triggering factors and the underling…”
Get full text

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies by Dalakas, Marinos C.

“…The main IgG4 antibody–mediated neurological disorders (IgG4-ND) include MuSK myasthenia; CIDP with nodal/paranodal antibodies to Neurofascin-155,…”
Get full text

Stiff-person syndrome and related disorders — diagnosis, mechanisms and therapies by Dalakas, Marinos C.

“…Stiff-person syndrome (SPS) is the prototypical and most common autoimmune neuronal hyperexcitability disorder. It presents with stiffness in the limbs and…”
Get full text

Advances in the diagnosis, pathogenesis and treatment of CIDP by Dalakas, Marinos C

“…Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic autoimmune neuropathy. In this Review, Marinos Dalakas provides an update…”
Get full text

Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications by Dalakas, Marinos C

“…The inflammatory myopathies constitute a heterogeneous group of acquired myopathies that have in common the presence of endomysial inflammation. Based on…”
Get full text

Advances in the therapeutic algorithm for myasthenia gravis by Dalakas, Marinos C.

“…New biologics are rapidly opening up target-specific therapeutic opportunities for myasthenia gravis (MG) — an autoimmune disease caused by antibodies against…”
Get full text

The immunobiology of autoimmune encephalitides by Alexopoulos, Harry, Dalakas, Marinos C.

“…Autoimmune encephalitides, with an estimated incidence of 1.5 per million population per year, although described only 15 years ago, have already had a…”
Get full text

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies by Dalakas, Marinos C.

“…Polyneuropathy with immunoglobulin M (IgM) monoclonal gammopathy is the most common paraproteinemic neuropathy, comprising a clinicopathologically and…”
Get full text

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies by Dalakas, Marinos C.

“…Describe the unique functions of immunoglobulin G4 (IgG4) in IgG4-neurologic disorders (IgG4-ND) and explain why, in contrast to their IgG1-counterparts, they…”
Get full text

Unconvincing Evidence of SARS-CoV-2-Associated Myositis in Autopsied Muscles by Dalakas, Marinos C

Get more information

Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome: Should There Be More to Come? by Dalakas, Marinos C.

Get full text